Odd Terje Brustugun

13PUBLICATIONS
38CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Oct 23, 2026
Molecular, histopathological, and clinical risk factors for overall metastatic disease and brain metastases in surgically resected stage I-III lung cancer.

|Jan 25, 2026
Profiling of Extracellular Vesicles of Non-Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance.

Albano Cáceres-Verschae, Petra Hååg, Sofia Joelsson

|Jan 19, 2024
Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer.

Anne Pernille Harlem Dyrbekk, Abdirashid Ali Warsame, Pål Suhrke

|Mar 11, 2023
Real-World Data on EGFR and ALK Testing and TKI Usage in Norway-A Nation-Wide Population Study.

Inger Johanne Zwicky Eide, Yngvar Nilssen, Elin Marie Stensland

|Jul 27, 2022
Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer.

Zeinab Kosibaty, Odd Terje Brustugun, Inger Johanne Zwicky Eide

|Apr 27, 2022
Factors affecting outcome in resected EGFR-mutated lung cancer.

Inger Johanne Zwicky Eide, Yngvar Nilssen, Marius Lund-Iversen

Pageof 3

Frequent Collaborators

4 joint publications

Inger Johanne Zwicky Eide

3 joint publications

Simon Ekman

3 joint publications

Marius Lund-Iversen

2 joint publications

Branislava Stankovic